According to a recent LinkedIn post from Cooler Heads, the company is highlighting a patient experience using its Amma scalp cooling device during chemotherapy. The post emphasizes that the patient reportedly retained about 60% of her hair while undergoing TCHP treatment and suggests that scalp cooling may also support hair regrowth even when hair loss occurs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn content describes Amma as an FDA-cleared scalp cooling device intended for adult cancer patients receiving treatment for solid tumors. For investors, this focus on real-world patient outcomes and regulatory clearance may underscore product-market fit in a specialized oncology-support niche, potentially supporting adoption, reimbursement discussions, and long-term revenue prospects in the supportive cancer care market.